methoxyflurane has been researched along with Acute Coronary Syndrome in 1 studies
Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180)
methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The unfavourable influence of morphine on the pharmacokinetics of ticagrelor resulting in weaker and retarded antiplatelet effect in patients with acute coronary syndrome (ACS) has been previously shown." | 9.41 | ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. ( Adamski, P; Buszko, K; Gasior, M; Gorący, J; Kleinrok, A; Kosobucka, A; Kubica, A; Kubica, J; Lesiak, M; Nadolny, K; Navarese, E; Niezgoda, P; Wojakowski, W, 2021) |
| "The unfavourable influence of morphine on the pharmacokinetics of ticagrelor resulting in weaker and retarded antiplatelet effect in patients with acute coronary syndrome (ACS) has been previously shown." | 5.41 | ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. ( Adamski, P; Buszko, K; Gasior, M; Gorący, J; Kleinrok, A; Kosobucka, A; Kubica, A; Kubica, J; Lesiak, M; Nadolny, K; Navarese, E; Niezgoda, P; Wojakowski, W, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kubica, A | 1 |
| Kosobucka, A | 1 |
| Niezgoda, P | 1 |
| Adamski, P | 1 |
| Buszko, K | 1 |
| Lesiak, M | 1 |
| Wojakowski, W | 1 |
| Gasior, M | 1 |
| Gorący, J | 1 |
| Kleinrok, A | 1 |
| Nadolny, K | 1 |
| Navarese, E | 1 |
| Kubica, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction[NCT04476173] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for methoxyflurane and Acute Coronary Syndrome
| Article | Year |
|---|---|
ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial.
Topics: Acute Coronary Syndrome; Analgesics; Carbidopa; Drug Combinations; Humans; Levodopa; Methoxyflurane; | 2021 |